Hepatitis C News and Research

Latest Hepatitis C News and Research

Virginia Mason first to use non-invasive FibroScan technology to evaluate liver diseases

Virginia Mason today becomes the first in the Pacific Northwest to use non-invasive FibroScan technology to evaluate disease stage in patients diagnosed with liver ailments.

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

The application for European marketing authorisation of faldaprevir, a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency (EMA).

26 Nov 2013

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

New method uses lab-on-a-chip device and cell phone to determine concentration of molecules

In developing nations, rural areas, and even one's own home, limited access to expensive equipment and trained medical professionals can impede the diagnosis and treatment of disease.

21 Nov 2013

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

A special issue on Helicobacter pylori has been published by Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Gut Microbes have been authored by world-class investigators and provide new insights into the pathophysiology, diagnosis, prevention, and treatment of this microbe.

20 Nov 2013

Study suggests potential new treatment for seizures

A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure. The discovery hinges on a new understanding of the complex molecular chain reaction that occurs when the brain is exposed to too much ammonia.

17 Nov 2013

HIVMA's updated HIV care guidelines show doctors should focus on common health conditions

The HIV Medicine Association of the Infectious Diseases Society of America has updated its HIV care guidelines to reflect the fact that people with HIV are now living normal life spans, and their physicians need to focus on preventive care, including screening for high cholesterol, diabetes and osteoporosis.

15 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

FOXO3 transcription factor may protect against alcohol-induced liver injury

New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis.

11 Nov 2013

Scientist shows how immune system 'attacks' liver cells during hepatitis by using JunB gene

Viral infections are the primary cause of liver inflammation or hepatitis, affecting hundreds of millions of people all over the world, and they represent a public health problem worldwide.

10 Nov 2013

Diagnostic technology advancing but barriers prevent integration into care, IDSA report warns

Despite advances in diagnostic technology, there is an urgent need for tests that are easy to use, identify the bug causing an infection and provide results faster than current tests, according to a report from the Infectious Diseases Society of America published today in a special supplement to Clinical Infectious Diseases.

7 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

AGA publishes HCV Clinical Decision Tool for management of HCV-positive patients

The American Gastroenterological Association Clinical Decision Tool for the Screening and Evaluation of Hepatitis C will help gastroenterologists in the early management of HCV-positive patients, according to a new paper in Gastroenterology, the official journal of the American Gastroenterological Association. Chronic HCV has a significant impact on the adult population and is a disease for which much progress has been made in its treatment.

6 Nov 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Virginia Mason first to use non-invasive FibroScan technology to evaluate liver diseases

Newly identified protein could prove promising new drug target for AIDS

Study brings effective hepatitis C cure closer to reality

Merck announces approval of NOXAFIL delayed-release tablets by FDA

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

Transgene welcomes SillaJen’s intention to acquire Jennerex

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

New method uses lab-on-a-chip device and cell phone to determine concentration of molecules

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

Study suggests potential new treatment for seizures

HIVMA's updated HIV care guidelines show doctors should focus on common health conditions

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

FOXO3 transcription factor may protect against alcohol-induced liver injury

Scientist shows how immune system 'attacks' liver cells during hepatitis by using JunB gene

Diagnostic technology advancing but barriers prevent integration into care, IDSA report warns

New treatment option for patients with most difficult-to-treat forms of hepatitis C

AGA publishes HCV Clinical Decision Tool for management of HCV-positive patients

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in